TABLE 2.
Cox proportional hazard regression analysis of progression‐free survival of 64 nasopharyngeal carcinoma patients
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p‐Value | HR (95% CI) | p‐Value | |
| Age a | 0.99 (0.95–1.03) | 0.68 | ||
| Sex (men vs. women) | 0.99 (0.22–4.44) | 0.99 | ||
| Stage a | 2.86 (1.22–6.71) | 0.016 * | 2.60 (1.10–6.14) | 0.030 |
| Histologic type (WHO classification 3 vs. others) | 0.62 (0.19–1.99) | 0.42 | ||
| Therapy (CRT vs. others) | 1.47 (0.41–5.30) | 0.56 | ||
| ER⍺ (+ vs. –) b | 3.16 (0.96–10.38) | 0.058 | ||
| Aromatase (+ vs. –) b | 2.58 (0.86–7.77) | 0.092 | ||
| ZEBRA (+ vs. –) b | 4.25 (1.28–14.13) | 0.018 * | 3.58 (1.08–11.87) | 0.037 |
Note: Statistically significant values (p < 0.05) are in boldface.
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
a
Data were evaluated as continuous value.
b
ER⍺, aromatase, and ZEBRA status was evaluated by immunohistochemistry (IHC), and the cutoff values were 10%, 20%, and 20%, respectively, determined from the median value of IHC of each positivity.
*
Data were considered significant in univariate analysis and examined in multivariate analysis.